Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

Ch Li, Robert Bies, Y. Wang, Mr Sharma, S. Karovic, L. Werk, Mj Edelman, Aa Miller, Ee Vokes, A. Oto, Mj Ratain, Lh Schwartz, Ml Maitland

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.

Original languageEnglish (US)
Pages (from-to)43-50
Number of pages8
JournalClinical and Translational Science
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Growth kinetics
Tumor Burden
Tumors
Imaging techniques
Growth
Neoplasms
Disease-Free Survival
Lung Neoplasms
Clinical Trials
Oncology
Response Evaluation Criteria in Solid Tumors
Radiologists

Keywords

  • Antineoplastic agents/pharmacology
  • Clinical trials
  • Humans
  • Lung neoplasms/drug therapy
  • Models
  • Response Evaluation Criteria in Solid Tumors
  • Statistical
  • Tomography
  • X-ray computed

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. / Li, Ch; Bies, Robert; Wang, Y.; Sharma, Mr; Karovic, S.; Werk, L.; Edelman, Mj; Miller, Aa; Vokes, Ee; Oto, A.; Ratain, Mj; Schwartz, Lh; Maitland, Ml.

In: Clinical and Translational Science, Vol. 9, No. 1, 01.02.2016, p. 43-50.

Research output: Contribution to journalArticle

Li, C, Bies, R, Wang, Y, Sharma, M, Karovic, S, Werk, L, Edelman, M, Miller, A, Vokes, E, Oto, A, Ratain, M, Schwartz, L & Maitland, M 2016, 'Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling', Clinical and Translational Science, vol. 9, no. 1, pp. 43-50. https://doi.org/10.1111/cts.12384
Li, Ch ; Bies, Robert ; Wang, Y. ; Sharma, Mr ; Karovic, S. ; Werk, L. ; Edelman, Mj ; Miller, Aa ; Vokes, Ee ; Oto, A. ; Ratain, Mj ; Schwartz, Lh ; Maitland, Ml. / Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. In: Clinical and Translational Science. 2016 ; Vol. 9, No. 1. pp. 43-50.
@article{8fe606ace315430194f037f6b6d2fbec,
title = "Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling",
abstract = "Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.",
keywords = "Antineoplastic agents/pharmacology, Clinical trials, Humans, Lung neoplasms/drug therapy, Models, Response Evaluation Criteria in Solid Tumors, Statistical, Tomography, X-ray computed",
author = "Ch Li and Robert Bies and Y. Wang and Mr Sharma and S. Karovic and L. Werk and Mj Edelman and Aa Miller and Ee Vokes and A. Oto and Mj Ratain and Lh Schwartz and Ml Maitland",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/cts.12384",
language = "English (US)",
volume = "9",
pages = "43--50",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

AU - Li, Ch

AU - Bies, Robert

AU - Wang, Y.

AU - Sharma, Mr

AU - Karovic, S.

AU - Werk, L.

AU - Edelman, Mj

AU - Miller, Aa

AU - Vokes, Ee

AU - Oto, A.

AU - Ratain, Mj

AU - Schwartz, Lh

AU - Maitland, Ml

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.

AB - Quantitative assessments of tumor burden and modeling of longitudinal growth could improve phase II oncology trials. To identify obstacles to wider use of quantitative measures we obtained recorded linear tumor measurements from three published lung cancer trials. Model-based parameters of tumor burden change were estimated and compared with similarly sized samples from separate trials. Time-to-tumor growth (TTG) was computed from measurements recorded on case report forms and a second radiologist blinded to the form data. Response Evaluation Criteria in Solid Tumors (RECIST)-based progression-free survival (PFS) measures were perfectly concordant between the original forms data and the blinded radiologist re-evaluation (intraclass correlation coefficient = 1), but these routine interrater differences in the identification and measurement of target lesions were associated with an average 18-week delay (range, -20 to 55 weeks) in TTG (intraclass correlation coefficient = 0.32). To exploit computational metrics for improving statistical power in small clinical trials will require increased precision of tumor burden assessments.

KW - Antineoplastic agents/pharmacology

KW - Clinical trials

KW - Humans

KW - Lung neoplasms/drug therapy

KW - Models

KW - Response Evaluation Criteria in Solid Tumors

KW - Statistical

KW - Tomography

KW - X-ray computed

UR - http://www.scopus.com/inward/record.url?scp=84958655385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958655385&partnerID=8YFLogxK

U2 - 10.1111/cts.12384

DO - 10.1111/cts.12384

M3 - Article

C2 - 26790562

AN - SCOPUS:84958655385

VL - 9

SP - 43

EP - 50

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 1

ER -